Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis

Risankizumab, a fully human IgG monoclonal antibody inhibitor of IL-23, is a therapeutic agent currently in late stage development for use in the treatment of moderate-to-severe plaque psoriasis. It is a biologic agent similar to guselkumab and tildrakizumab which targets IL-23 specifically, and has...

Descripción completa

Detalles Bibliográficos
Autores principales: Haugh, Isabel M, Preston, Allie K, Kivelevitch, Dario N, Menter, Alan M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237136/
https://www.ncbi.nlm.nih.gov/pubmed/30518998
http://dx.doi.org/10.2147/DDDT.S167149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6237136/
https://www.ncbi.nlm.nih.gov/pubmed/30518998
http://dx.doi.org/10.2147/DDDT.S167149

Ejemplares similares